Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05492851 · ClinicalTrials.gov registry record · Phase 4
Trial Comparing Three Single Dose Injections for Knee Osteoarthritis
A Phase 4 study, sponsored by Ohio State University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT05492851: Clinical Trial Phase 4 study, sponsored by Ohio State University.
NCT05492851 is a Phase 4 study that was terminated before completion, run by Ohio State University. The registered enrollment target is 6 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05492851, a Phase 4 study, was terminated before completion, sponsored by Ohio State University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study is a 3-arm, double-blind, randomized trial comparing the clinical outcomes of Zilretta, Synvisc One, and Monovisc for knee OA.
Primary Outcome
KOOS Pain evaluates short-term and long-term pain in subjects with knee injury and osteoarthritis. Scores range from 0-100 where 100 represents no knee pain.
Interventions
- DRUG Zilretta
- DRUG Synvisc-One 48 MG in 6 ML Prefilled Syringe
- DRUG Monovisc 88 MG Per 4 ML Prefilled Syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2022-08-02 |
| Est. Completion | 2023-01-11 |
| Phase | Phase 4 |
Why NCT05492851 stopped before completion
NCT05492851 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which Zilretta is the first listed.
NCT05492851 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05492851 about?
NCT05492851 is a clinical study titled "Trial Comparing Three Single Dose Injections for Knee Osteoarthritis". This study is a 3-arm, double-blind, randomized trial comparing the clinical outcomes of Zilretta, Synvisc One, and Monovisc for knee OA.
What is the current status of trial NCT05492851?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2022-08-02. Estimated completion is 2023-01-11.
What interventions are being tested in trial NCT05492851?
The interventions under investigation include: Zilretta (DRUG), Synvisc-One 48 MG in 6 ML Prefilled Syringe (DRUG), Monovisc 88 MG Per 4 ML Prefilled Syringe (DRUG).
Who is sponsoring clinical trial NCT05492851?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05492851's enrollment target sits among peer trials
6 1983rd of 2000 higher than 12 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI